Amendment_One_N01CN77019-18.pdf

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:

(a) By completing items 8 and 15, and returning or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

E. IMPORTANT: Contractor is not is required to sign this document and return copies to the issuing office.

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE

2. AMENDMENT/MODIFICATION NUMBER 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQUISITION NUMBER 5. PROJECT NUMBER (If applicable)

7. ADMINISTERED BY (If other than Item 6) CODE

STANDARD FORM 30 (REV. 11/2016)

Prescribed by GSA FAR (48 CFR) 53.243

FACILITY CODE

9A. AMENDMENT OF SOLICITATION NUMBER

9B. DATED (SEE ITEM 11)

10A. MODIFICATION OF CONTRACT/ORDER NUMBER

10B. DATED (SEE ITEM 13)

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended. is not extended.

12. ACCOUNTING AND APPROPRIATION DATA (If required) copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted;

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.

IT MODIFIES THE CONTRACT/ORDER NUMBER AS DESCRIBED IN ITEM 14.

CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER

NUMBER IN ITEM 10A.

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D. OTHER (Specify type of modification and authority)

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15C. DATE SIGNED

15A. NAME AND TITLE OF SIGNER (Type or print)

16C. DATE SIGNED

16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

PAGE OF PAGES

6. ISSUED BY CODE

8. NAME AND ADDRESS OF CONTRACTOR (Number, street, county, State and ZIP Code) (X)

CODE

15B. CONTRACTOR/OFFEROR

(Signature of person authorized to sign)

16B. UNITED STATES OF AMERICA

(Signature of Contracting Officer)

Previous edition unusable

Purpose: To add missing Attachments 1-26 and 28

National Institutes of Health National Cancer Institute Frederick, MD 21701

TO ALL CONTRACTORS

N01CN77019-18

05/08/2018 belangern Typewritten Text belangern Typewritten Text belangern Typewritten Text belangern Typewritten Text

PACKAGING AND DELIVERY OF PROPOSAL ATTACHMENT 1

September 28, 2016 Page 1 of 2

Attachment 1 - Packaging and Delivery of Proposals for Use with the NIH electronic Contract Proposal Submission (eCPS) Website

I. PROPOSAL SUBMISSION

A. eCPS

Offerors may propose on more than one pool under the PREVENT Preclinical Cancer Drug Development Program (Efficacy, CGMP, Toxicology/Pharmacology) but must submit separate, clearly-labeled Technical and Business proposals for each pool.

1. Proposals must be submitted via the electronic Contract Proposal Submission (eCPS) website at https://ecps.nih.gov.

2. Proposals submitted by facsimile or e-mail will not be accepted.

3. Follow the “How to Submit an Electronic Proposal” instructions provided on the eCPS website at: https://ecps.nih.gov/home/howto. Please note that creating an account to submit may take up to three (3) business days. Please apply for a new account early to allow enough time for the registration process.

4. Offerors are solely responsible for submitting proposals and any modifications or revisions so as to reach the Government office designated above by the date and time specified in the solicitation. If your proposal is not received by the date and time specified in the solicitation, it will be considered a “late proposal,” in accordance with FAR 52.215-1, Instructions to Offerors- Competitive Acquisitions and HHSAR 352.215-70, Late Proposals and Revisions (December 18, 2015).

B. Creating and Naming Files:

1. Create one PDF file of your Technical Proposal, including all attachments. The

Technical Proposal should be created in a PDF format that enables word searches to the maximum extent practicable. Forms and/or documents requiring signature(s) may be scanned, but must be merged into the Technical Proposal PDF file.

2. Create one PDF file of your Business Proposal, including all attachments: The Business Proposal should be created in a PDF format that enables word searches to the maximum extent practicable. Forms and/or documents requiring signature(s) may be scanned, but must be merged into the Business Proposal PDF file. Additionally, the “Breakdown of Proposed Estimated Costs (plus Fee) with Excel Spreadsheet” (http://oamp.od.nih.gov/sites/default/files/DGS/contracting-forms/spshexcl_dec2012.xlsx) must be included in the Business Proposal.

3. Create your Business Document Excel. The Excel file should be the “Breakdown of Proposed Estimated Costs (plus Fee) with Excel Spreadsheet” (http://oamp.od.nih.gov/sites/default/files/DGS/contracting-forms/spshexcl_dec2012.xlsx) included in the Business Proposal in its original Excel format, not PDF. Multiple Excel files may be included, as necessary.

https://ecps.nih.gov/ https://ecps.nih.gov/home/howto http://oamp.od.nih.gov/sites/default/files/DGS/contracting-forms/spshexcl_dec2012.xlsx http://oamp.od.nih.gov/sites/default/files/DGS/contracting-forms/spshexcl_dec2012.xlsx http://oamp.od.nih.gov/sites/default/files/DGS/contracting-forms/spshexcl_dec2012.xlsx http://oamp.od.nih.gov/sites/default/files/DGS/contracting-forms/spshexcl_dec2012.xlsx

PACKAGING AND DELIVERY OF PROPOSAL ATTACHMENT 1

September 28, 2016 Page 2 of 2

4. Each of the proposals, Technical and Business, must be separate and complete in itself.

Do not reference one proposal in another.

5. File naming convention: It is requested that the filenames for your Technical Proposal, Business Proposal, and Excel Workbook include the name of the offeror, the solicitation number and the type of proposal (i.e., Technical, Business, or Excel Workbook).

Examples:

Technical Proposal: XYZ Company_NIHAI2012001_Technical.pdf Business Proposal: XYZ Company_NIHAI2012001_Business.pdf Excel Workbook: XYZ Company_NIHAI2012001_Business.xlsx

II. FORMATTING AND PAGE LIMITATIONS

A. Formatting for proposals

1. Proposals shall not include links to internet web site addresses (URLs) or otherwise direct readers to alternate sources of information.

2. Font size must be 10 to 12 points.

3. Spacing should be no more than 15 characters per inch. Within a vertical inch, there must be no more than six lines of text.

4. Margins must be at least one-inch on all sides.

5. Failure to adhere to the formatting requirements above may impact whether your proposal is reviewed in its entirety.

B. Page limitations:

1. The total page count of the Technical proposal shall not exceed 120 pages for the CGMP and Efficacy pools. The total page count of the Technical proposal shall not exceed 150 pages for the Toxicology/Pharmacology pool. Proposal pages shall be numbered “Page 1 of 120, “Page 2 of 120” etc. The page limits for the Technical Proposals excludes any sample task order proposals and the proposal for Task Order #1 Contract Orientation and Kickoff Meeting.

2. Total page count does not include: Title and Back Page; Table of Contents, Resumes, Appendixes & Attachments; and Section Dividers that do not contain information other than title of Section.

3. Pages in excess of this limitation will be removed from the proposal and will not be considered.

PROPOSAL INTENT RESPONSE FORM

RFP No:

RFP Title:

Please review the Request for Proposal (RFP). Furnish the information requested below and return this page to the Contracting Officer/Contract Specialist identified on Section A-Solicitation/Contract Form by

Your expression of intent is not binding but will greatly assist us in planning for proposal evaluation.

Choose one of the following Options:

Do intend to submit a proposal Do Not intend to submit a proposal

If you are not responding to this RFP, please provide your reason(s):

Please provide the following contact information:

Name (First, Middle Initial, Last):

Title:

Organization:

E-mail:

Attachment Three

PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM

BACKGROUND AND INTRODUCTION

RFP NO. N01CN77019-18

The Division of Cancer Prevention (DCP) is a principal Division of the National Cancer Institute (NCI) devoted to cancer prevention research. Research supported by the DCP encompasses a continuum of preclinical and clinical studies, including a better understanding and elucidation of cancer initiation processes, methods of identifying individuals at risk for cancers, and the development of early cancer detection methodologies and cancer preventive interventions, with the overarching goal to prevent invasive cancer and associated deaths in human subjects. The PREVENT Cancer Preclinical Drug Development Program (PREVENT;

http://prevention.cancer.gov/major-programs/prevent-cancer-preclinical) was formally launched by the DCP in 2011 as a contract-based program with its primary mission to advance the preclinical development of cancer-preventive interventions and intermediate biomarkers, and to support/enable their clinical translation. The PREVENT Program accepts concept applications from academia, government, small businesses, and the pharmaceutical industry, and selects meritorious projects through peer review and organizational prioritization processes. Approved projects are entered into the appropriate stage of the PREVENT pipeline, which is supported by NCI contract resources, and implemented in a milestone-driven manner from early proof of concept studies to secondary testing, and the final steps of Investigational New Drug (IND) applications-enabling studies. Since its inception, the PREVENT Program has partnered with researchers in the extramural community and supported over 74 projects, for which 73 Task Orders were awarded to two separate pools of competitively selected prime contract holders with requisite technical capabilities in the areas of (1) in vivo development/animal efficacy/biomarker development, and (2) toxicology/pharmacology testing. One clinical trial has been initiated on a PREVENT-supported cancer vaccine, while INDs are expected to be filed for five other PREVENT-supported projects.

The PREVENT Program’s current scientific focus areas include cancer immunoprevention (e.g.

vaccines), anti-inflammatory approaches, molecularly targeted chemoprevention agents, drug repurposing, and toxicity reduction strategies. Because successful cancer prevention requires long term (possibly life-long) use of preventive agents in healthy subjects, a rigorous preclinical development path must be followed for any lead intervention development projects not only to establish and confirm their preventive efficacy profiles, but also to demonstrate safety in pertinent nonclinical models, thereby attaining the highest achievable benefit/risk ratio before they can progress to clinical trials.

Cancer preventive vaccines have the potential to provide long-lasting protective immunity virtually in the absence of long-term toxicity concerns. Recent advances in tumor immunology and anticancer immunotherapies have uncovered the host immune system’s capacity to mount effective antitumor immune responses to tumor-specific or tumor-associated antigens and counter cancer growth. When tumor-derived immune suppression is blocked by immune checkpoint inhibitors in the established tumor immune microenvironment, the immune system can exert more robust antitumor immune responses. It is highly conceivable that cancer vaccines targeting certain immunogenic tumor-associated antigens may induce more effective antitumor http://prevention.cancer.gov/major-programs/prevent-cancer-preclinical

Attachment Three immunity if given before or early in the tumorigenic process, and thus may prevent or deter the development of malignant lesions.

The development and introduction of cancer immunopreventive agents, such as vaccines, remain one of the highest priorities for the PREVENT Program. As the PREVENT project portfolio matures, multiple immunoprevention projects are expected to progress to the late stage of preclinical development, which will necessitate the supply of clinical-grade vaccines and other immunomodulatory agents in support of IND-enabling studies. To meet the anticipated technical needs in the PREVENT pipeline, the NCI has a requirement for product development-oriented services, related to clinical-grade product development and manufacturing support, for promising biopharmaceutical agents identified through the PREVENT Program. The agent production services will encompass activities commonly associated with the development of biopharmaceutical products that are required for IND and/or Biologic License Applications (BLAs). These services will be made available for candidate immunopreventive agents arising from academia, the private sector, or other sources that are selected through the PREVENT pipeline’s agent development processes as described above. The early and rapid identification of subjects at risk for cancers is highly critical to successful implementation of effective cancer preventive interventions and risk management. Based on emerging data and newer evidence, the development and production of diagnostic reagents or specific assay methodologies may become necessary in the ensuing years. For that purpose, this third component includes services supportive of new methodologies for early cancer detection and high-risk cohort identification.

Along with the existing components that support in vivo efficacy testing and biomarker development as well as toxicology and pharmacology testing, it will enhance the capability and capacity of the PREVENT Program to support the development of biopharmaceutical products, in direct support of the mission of the Division of Cancer Prevention, which is to prevent invasive cancer and associated deaths.

The purpose of this solicitation is to procure Research & Development services to support the PREVENT Program in the areas of (1) in vivo development/animal efficacy/biomarker development, (2) preclinical product development and CGMP manufacturing of biopharmaceutical agents, and (3) toxicology/pharmacology testing. In order to meet the demands for all services in a timely and proactive manner, the NCI intends to award contracts that provide a suite of technical task support services, using the Indefinite Delivery-Indefinite Quantity (IDIQ) contract mechanism. Under the IDIQ mechanism, the NCI will award Task Orders for specific activities that meet technical requirements tailored for each identified PREVENT project’s needs. While the overall suite of services listed is comprehensive, the intent is to provide individual services on a case-by-case basis for a diverse collection of candidate agents, rather than carry a single candidate product through an entire preclinical development pathway. These services are intended to help investigators in various scientific disciplines obtain critical data needed to advance their agents further through the PREVENT pipeline, acquire additional funding from other sources, gain prospective partnerships (either for further development or to support Phase I trials), fulfill regulatory requirements, and/or complete studies needed to apply for an IND and enter a Phase I trial.

Attachment 4 01/25/2018

N01CN77019-18

IDIQ STATEMENT OF WORK

PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers

Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, materials, equipment, and facilities, not otherwise provided by the Government, as needed to perform the Statement of Work.

1) SCOPE

This IDIQ will be administered and used primarily to support the PREVENT Program initiatives as necessary to help the Program achieve its mission. More specifically, the contract shall support the development of potential cancer preventive agents, vaccines, or other immunopreventive agents, by conducting preclinical animal studies for cancer preventive efficacy evaluation, employing detailed pharmacological and/or immunological studies, determining pharmacodynamic (PD) and/or immunodynamic (ID) effects of test agents, and correlating pharmacokinetic and/or immunologic biomarker profile(s) with the effectiveness of test agents. The primary endpoint of the efficacy studies shall be to prevent the development of invasive cancers whereas the biomarker studies will identify and validate endpoints, which correlate with or represent the effectiveness of given chemopreventive agents, vaccines, or other immunopreventive agent. These endpoints might be measured in body fluids, normal or at risk tissue from the target, or in histopathologically altered tissue from the target organ(s).

Note to Offerors: Task Orders shall range in duration from 1 to 3 years. For purposes of proposal preparation, the Offerors shall assume that each Task Order will involve no more than two (2) agents and no more than two (2) routes of administration, using the number of animals ranging from 350 to 550 animals per Task Order. The Offerors shall provide judicious estimation, based on the literature and previously validated study protocols, on the number of specimens that require storage under the Task Order, but shall assume the maximum number of specimens for storage not to exceed 3,000.

2) GENERAL TASK ORDER REQUIREMENTS

Specific Task Orders will depend on the status of the candidate agent(s) or biomarkers in relation to an overall development plan and/or regulatory submission plan to the FDA. Tasks shall be conducted in accordance with quality oversight that is appropriate to the phase of the specific task and within all applicable and current federal, state, and local laws, codes, ordinances and regulations, as well as all applicable Public Health Service (PHS) Safety and Health provisions.

The following requirements shall apply to each Task Order:

2.1 PROJECT MANAGEMENT

1. Task Order Initiation Meeting and/or Teleconference: Within 10 calendar days after the effective date of the Task Order or before the start of any tasks, plan for and participate in an Initiation Meeting or Teleconference to review the Task Order requirements and timelines, discuss Task Order technical plans and approaches, and identify any anticipated problems/obstacles to completing the Task Order requirements. The Task Initiation Meeting will be attended by Contractor key personnel (including subcontractor personnel as appropriate), the Contracting Officer’s Representative (COR), and any other key personnel at the discretion of the COR and Contractor.

2. Develop, monitor, and modify the timelines, tasks, budgets, objectives and milestones as discussed with and/or prioritized by the COR before and during the performance of activities under the Task Order. If changes need to be made to the technical protocol at any time, updates shall be provided to the CO and COR immediately by teleconference or email and also documented as part of the quarterly progress reports for each Task Order. The CO and COR must provide concurrence and approval prior to the Contractor implementing any proposed change(s). Updates will include changes made and current project rationale.

3. The Principal Investigator (or equivalent) shall be responsible for overall compliance with quality requirements, project management and communication, tracking performance, monitoring and reporting on project status and progress, and recommending modifications to project requirements and timelines, including projects undertaken by subcontractors.

4. Key personnel or other senior staff coordinator(s) shall be available for ad hoc meetings/teleconferences with the COR immediately upon a meeting request.

5. Progress Review Meetings and Teleconferences

a. Plan and participate in Progress Review Meetings or Teleconferences, to be attended by Contractor key personnel (including subcontractor personnel as appropriate), the COR, the designated Subject Matter Experts, the Contracting Officer, any other key personnel at the discretion of the COR and Contractor, as necessary, at monthly intervals or as issues arise. The purpose of these meetings/teleconferences shall be to review and discuss:

1) ongoing and planned activities, protocols and associated data;

2) timelines for task initiation and completion, submission of data and other information;

3) any problems or deficiencies identified with respect to the accuracy, timeliness and completeness of data submitted; and

4) any other matters relevant to the technical and financial administration of the task.

b. The Contractor shall be responsible for:

1) preparing and distributing meeting/teleconference agendas and background materials at least one business day prior to each meeting/teleconference; and

2) preparing and submitting to the COR written summaries of all major decisions and action items resulting from such meetings and teleconferences within seven calendar days after each meeting/teleconference.

The following Quality Management requirement shall apply and be provided at the Base IDIQ level:

2.2 QUALITY MANAGEMENT

1. The Contractor shall demonstrate responsibility for the quality and applicable regulatory compliance of the materials and documentation generated per this Statement of Work (SOW). The Contractor shall have a quality management plan outlined in the proposal that describes how quality assurance is addressed within the organization, including quality management responsibilities, resources, training program, oversight of all subcontractors if applicable, and communication processes including timelines.

2.3 FACILITIES, ANIMALS, EQUIPMENT, AND OTHER RESOURCES

As outlined in the Task Order:

1. The Contractor shall provide facilities, equipment, space, training, and other resources to conduct work with potentially hazardous chemical or biological materials in compliance with all federal and NIH regulations in accordance with the guidelines including but not limited to those listed in the Addendum titled “References” as applicable.

2. The Contractor shall provide facilities, equipment, space, and other resources to conduct work in a manner to prevent cross-contamination with other materials.

3. All personnel, equipment, and facilities shall be compliant with applicable regulatory agency requirements in effect throughout the entire period of performance. The Contractor shall maintain quality assurance documentation to support adherence to these areas.

4. Animal Facility: The Contractor and any proposed subcontractor laboratories shall be accredited by or registered as follows:

a. The Contractor shall have an approved Animal Welfare Assurance from the Office of Extramural Research (OER), Office of Laboratory Animal Welfare (OLAW) (http://grants.nih.gov/grants/olaw/olaw.htm), Office of the Director, NIH, as required by Section I-43-30 of the PHS Policy on Humane Care and Use of Laboratory Animals. The Contractor shall maintain such assurance for the duration of this http://grants.nih.gov/grants/olaw/olaw.htm contract, and any subcontractors performing work under this contract involving the use of animals shall also obtain and maintain an approved Animal Welfare Assurance.

b. The Contractor and any subcontractors performing work under this contract shall be fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International or equivalent and maintain that accreditation for the life of the contract. Information about AAALAC accreditation is available at http://www.aaalac.org/accreditation/.

c. The Contractor and any subcontractors performing work under this contract shall comply with the PHS Policy on Humane Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/references/phspol.htm) and conduct work in compliance with recommendations established in the Guide for the Care and Use of Laboratory Animals (https://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf).

d. The Contractor and any subcontractors performing work under this contract shall comply with the Animal Welfare Act and Animal Welfare Regulations established by the United States Department of Agriculture (USDA), available at http://www.aphis.usda.gov/wps/portal/aphis/ourfocus/animalwelfare.

e. The Contractor’s Institutional Animal Care and Use Committee (IACUC) shall approve all animal procedures under this contract.

5. Animals: All animals for studies shall be furnished by the Contractor from established, reputable, known commercial breeders or shall be bred by the Contractor. The Contractor shall quarantine the animals for an appropriate period prior to placing them on test for studies and their release shall be documented by the attending American College of Laboratory Animal Medicine (ACLAM) veterinarian.

2.4 STORAGE AND SHIPPING

As outlined in the Task Order:

1. The Contractor shall be responsible for the overall management and conduct of the receipt, storage, retrieval, packaging and shipping of products, materials, and specimens, including obtaining appropriate licenses and permits, where applicable.

2. Receive and record products, materials, reagents, and specimens.

3. Store products, materials, and test samples at the specified temperature range and conditions in a secure area. Specific temperature ranges include, but are not limited to, liquid nitrogen, -80°C ± -10°C, -20°C ± -5°C, 4°C (2-8°C), and room temperature.

http://www.aaalac.org/accreditation/ http://grants.nih.gov/grants/olaw/references/phspol.htm https://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf https://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf http://www.aphis.usda.gov/wps/portal/aphis/ourfocus/animalwelfare

4. The conditions in all controlled temperature chambers shall be monitored and documented as appropriate for the level of regulatory compliance, as necessary.

5. Temperature chambers shall be qualified or validated as proposed by the Contractor and reviewed and approved by the COR.

6. The Contractor shall be responsible for retrieval, packaging, and shipping of materials to various domestic and international locations. Detailed shipping instructions will be supplied by the Government or the Contractor at the time of shipment as appropriate. When necessary, a documented shipping procedure compatible with all applicable regulations is to be established and followed. Temperatures maintained during shipping and storage shall be captured and documented. Packaging shall adhere to U.S. and international standards as applicable.

2.5 TRANSITION

At the completion of each Task Order or at any point as determined by the COR, the Contractor shall deliver the following items:

1. all data obtained from all work carried out under each Task Order by the Contractor, all subcontractors, and all third parties as designated by the COR;

2. all materials, critical reagents and/or reference materials remaining from the work carried out under each Task Order by the Contractor, all subcontractors, and all third parties as designated by the COR, unless otherwise instructed by the COR;

3. any critical reagents, references and/or materials developed under each Task Order by the Contractor, all subcontractors, and all third parties as designated by the COR, unless otherwise instructed by the COR; and

4. all files pertaining to each Task Order generated by the Contractor, all subcontractors, and all third parties as designated by the COR.

3) TASK AREAS

In performance of work under any Task Area, the Contractor shall comply with all applicable guidelines including, but not limited to, those listed in the Addendum to this SOW titled “References”. Services to be performed under this contract could include the following:

A. Preclinical Evaluation of Cancer Preventive Efficacy B. Evaluation and Validation of Intermediate Endpoints for Chemopreventive Agents C. Evaluation and Validation of Intermediate Endpoints for Immunopreventive Agents

Note to Offerors: To be considered for an award under this pool, Offerors are expected to demonstrate proficiency in Task Area A in their proposals, but need only demonstrate proficiency in Task Area B OR Task Area C.

For the purposes of this contract:

Chemopreventive agents – Chemical, pharmaceutical, and nutraceutical entities used to prevent cancer including, but not limited to, licensed pharmaceutical products; novel molecularly targeted small molecule compounds; natural products and derivatives; peptides;

and nucleic acid based materials.

Immunopreventive agents – Materials and products used to modulate the host immune system to prevent cancer including, but not limited to, monoclonal antibodies and derivatives of monoclonal antibodies; vaccines based on recombinant proteins, peptides, or nucleic acids (such as RNAs and DNAs) formulated with/without vaccine adjuvants and delivery systems;

and live, modified-live, and/or attenuated entities.

Note to Offerors: Contractors may need to be supported to a certain extent by the expertise and resources of other organizations or persons through consortia agreements, partnerships, subcontracts, and/or consultants. However, Contractors shall be responsible for ALL work performed and shall be responsible for project planning, initiation, implementation, management, and communication; evaluation, selection, and management of subcontractors; and for all deliverables specified in this contract and each awarded Task Order.

3.1 TASK AREA A: PRECLINICAL EVALUATION OF CANCER PREVENTIVE

EFFICACY

The Contractor shall determine cancer preventive efficacy of a given test agent (chemopreventive or immunopreventive) using animal models that include, but are not limited to, syngeneic tumor-graft, carcinogen-induced, and/or genetically engineered (transgenic) models of cancers of mammary gland, lung and bronchus, esophagus, colon and intestinal tract, prostate, bladder, skin, ovary and other gynecologic tissues, mouth, head and neck, pancreas, liver, and hematopoietic system. The Contractor shall select the animal model(s) most suited for each Task Order’s specific study objectives defined in the Task Order SOW and obtain approval from the COR before commencing all proposed tasks under each awarded Task Order.

Technical Requirements for Task Area A include one or more of the following:

1. The Contractor shall develop and/or update preclinical agent evaluation and development

2. plans in collaboration with the product investigator and COR, as necessary. Plans shall include preclinical study activities to be undertaken for a product efficacy evaluation.

Anticipated timelines for completion of tasks related to the activity shall be provided to the

COR.

3. The Contractor shall procure/obtain the test agent(s), unless provided by the NCI. The Contractor shall determine the purity, homogeneity, concentration, and stability of the test agents in administering vehicles and conditions of use as defined in each awarded Task Order SOW. If necessary, the Contractor shall perform chemical analysis of feed or diet concerning preventive agents to be administered.

4. The Contractor shall breed and maintain animal colonies of wild type rodents and specified transgenic rodents in sufficient numbers for preventive efficacy testing purposes. The Contractor shall use animal facilities that meet all requirements specified in each awarded Task Order (e.g. special barrier facilities), where applicable.

5. The Contractor shall administer chemopreventive agents by different routes specified in the Task Order SOW, including but not limited to diet, gavages, topical, inhalation, injection, or pellet implantation. If more than one route of administration must be studied, the Contractor shall propose appropriate routes of administration tailored for the Task Order-specified study objectives and obtain approval from the COR before commencing all proposed tasks under each awarded Task Order.

6. The Contractor shall administer immunopreventive agents (e.g. vaccines and adjuvants) using appropriate routes of administration as specified in the Task Order SOW. If more than one route of administration must be studied, the Contractor shall propose appropriate routes of administration tailored for the Task Order-specified study objectives and obtain approval from the COR before commencing all proposed tasks under each awarded Task Order.

7. The Contractor shall design research studies, outlining key determinants including but not limited to the order and timing of administration of carcinogen(s), oncogene- or tumor promoting-gene inducing/activating agents, hormones, and/or a given test agent (chemopreventive or immunopreventive) to laboratory animals, as well as different dosing intervals and different doses of test agents, if required. The Contractor shall clearly indicate the number of animals to be used in each proposed technical task supported by appropriate statistical considerations including, but not limited to, power calculations and appropriate corrections for multiple comparisons. The Contractor shall obtain approval from the COR on the research outline before commencing all proposed tasks under each awarded Task Order.

8. The Contractor shall conduct the approved studies to evaluate and determine cancer preventive efficacies of test agents (chemopreventive and/or immunopreventive) using clinical parameters including, but not limited to, appearance, body weight, food and water intake, tumor growth rates/incidence, and survival. If warranted, the Contractor shall employ appropriate tumor imaging technologies (e.g. CT, PET, MRI, ultrasound, bioluminescence, fluorescence) for monitoring tumor growth and progression in live animals.

9. The Contractor shall perform pharmacokinetic studies in appropriate laboratory animals if specified in awarded Task Orders, and shall correlate with pharmacodynamic (PD) effects (see 4.2).

10. The Contractor shall collect and preserve blood and other body fluid specimens over the course of in-life animal studies, if specified in each awarded Task Order SOW, for intermediate biomarker studies. The Contractor shall maintain all collected study biospecimens under appropriate storage condition(s) until use.

11. The Contractor shall carry out gross necropsies, and collect and preserve study biospecimens including, but not limited to, whole blood, peripheral blood mononuclear cells (PBMC), plasma, serum, urine, other body fluids (e.g. ascites), lymphoid and other organ tissues, and tumor samples, as specified in each awarded Task Order SOW. The Contractor shall maintain all collected study biospecimens under appropriate storage condition(s) until use.

Specifically, the Contractor shall store collected tissues at either 4°C (2-8°C), -20°C ± -5°C, -80°C ± -10°C, or liquid nitrogen, according to the instructions and/or requirements of the experimental protocol on the specific Task Order issued. The Contractor shall keep plasma, sera or other body fluids at appropriate storage temperature (4°C [2-8°C], -20°C ± -5°C, -80°C ± -10°C) until use, pursuant to the instructions or specifications for specified assays under each awarded Task Order.

12. The Contractor shall carry out histopathological examination of selected organ and tumor tissues from control and treated animals as specified in each awarded Task Order SOW. The Contractor shall also carry out immunohistochemistry (IHC) and other appropriate assay methods to evaluate tumor grades and disease stage, if specified in each awarded Task Order.

13. The Contractor shall report all collected tumor growth data including, but not limited to, tumor growth rates, tumor incidence, tumor multiplicity, and tumor latency as specified in each awarded Task Order SOW. The Contractor shall perform statistical analyses of the data and include in the report, as required, means and standard deviations as well as identifying statistically significant and insignificant findings.

14. The Contractor shall ship some or all biospecimens with technical documentation to other investigators at the direction of the Task Order COR (also see 3.4).

3.2 TASK AREA B: EVALUATION AND VALIDATION OF INTERMEDIATE

ENDPOINTS FOR CHEMOPREVENTIVE AGENTS

The Contractor shall conduct intermediate endpoint assays using biospecimens that include, but are not limited to, blood, PBMC, plasma, sera, other body fluids, isolated splenocytes, lymphocytes, tumor cells, other specific cell populations, and tissues, collected from preclinical cancer prevention efficacy studies for given test agents. The relevant tissues shall be supplied to the Contractor unless otherwise specified in the Task Order. The Contractor shall select the intermediate endpoint assays most suited for each Task Order’s specific study objectives defined in the Task Order SOW, and obtain approval from the COR before commencing all proposed tasks under each awarded Task Order.

Technical Requirements for Task Area B include one or more of the following:

1. The Contractor shall develop and validate intermediate endpoint assays that shall examine changes in cellular, genomic, epigenomic, proteomic, and/or metabolomic profiles in relevant biospecimens, as specified in each awarded Task Order SOW. Endpoints to be examined shall include, but are not limited to, quantitative and/or qualitative profiles of specific cell population(s) in circulation (e.g. circulating tumor cells) and/or organs, specific gene transcripts, microRNA (miRNA) and other small non-coding regulatory RNA species, DNA adducts, DNA methylation, histone modifications (e.g. acetylation, deacetylation, ubiquitination, phosphorylation, etc.), exosomes, proteins with/without post-translational modifications (e.g. phosphorylation, ubiquitination, glycosylation, etc.), peptides, and other macromolecular complexes.

2. The Contractor shall select and examine quantitative levels of appropriate intermediate endpoints that are proposed or understood to be involved in the molecular mechanism of action (MOA) of a given test agent, using the validated assays in relevant biospecimens, as specified in each awarded Task Order SOW.

3. The Contractor shall select and examine quantitative levels of appropriate intermediate endpoints that are not directly involved in the MOA, but proposed or understood to be correlated with the test agent’s cancer preventive effects, using the validated assays in relevant biospecimens as specified in each awarded Task Order SOW.

4. The Contractor shall determine pharmacokinetic endpoints directly related to the test agent (e.g. the parent compound and/or metabolites) if specified in the Task Order SOW (also see 4.1.8).

5. The Contractor shall present/report all collected intermediate endpoint data in tabular and/or graphic forms, perform statistical analyses of the data, and shall provide a written commentary regarding the results as specified in each awarded Task Order. Further, the Contractor shall correlate intermediate biomarker results with pharmacokinetic data, if applicable, and demonstrate pharmacodynamic (PD) effects. Furthermore, the Contractor shall correlate the PD effects with the effectiveness of a given agent and shall determine the PD correlates of protective efficacy.

3.3 TASK AREA C: EVALUATION AND VALIDATION OF INTERMEDIATE

ENDPOINTS FOR IMMUNOPREVENTIVE AGENTS

The Contractor shall conduct intermediate endpoint assays using biospecimens that include, but are not limited to, blood, PBMC, plasma, sera, other body fluids, isolated splenocytes, lymphocytes, and tissues, collected from preclinical cancer prevention efficacy studies for given test agents. The relevant tissues shall be supplied to the Contractor unless otherwise specified in the Task Order. The Contractor shall select the intermediate endpoint assays most suited for each Task Order’s specific study objectives defined in the Task Order SOW, and obtain approval from the COR before commencing all proposed tasks under each awarded Task Order.

Technical Requirements for Task Area C include one or more of the following:

1. The Contractor shall develop and validate intermediate endpoint assays that shall examine changes in humoral and/or cellular immune responses to vaccine, non-vaccine immunomodulatory agents, and/or select tumor antigens (Ags), using relevant biospecimens as specified in each awarded Task Order SOW. Endpoints to be examined shall include, but are not limited to, quantitative levels of Ag-specific antibodies, specific immune cell populations (e.g. Ag-presenting cells, T lymphocytes, B lymphocytes, natural killer cells, effector, suppressor, and memory T/B cell subsets, regulatory T/B cells, myeloid derived suppressor cells, etc.) in circulation and/or in organs and tumors, Ag-specific T helper cell population-related cytokine production profiles (e.g. Th1/Th2/Th17), cytotoxic T lymphocyte activity (CTL), and/or antibody dependent cellular cytotoxicity (ADCC), as specified in the Task Order SOW.

2. The Contractor shall determine immunogenic epitopes of vaccine antigens and/or select tumor antigens as specified in the Task Order SOW using appropriate application technologies including, but not limited to, synthetic peptide library-based methods with different assay readouts such as lymphoproliferation, cytokine production (e.g. interferon gamma ELISpot, ELISA), cytokine staining by flow cytometry, MHC binding, and antibody binding; peptide recovery from MHC complexes by mass spectrometry; and other molecular/biochemical/biophysical methods as specified in the Task Order.

3. The Contractor shall develop and validate intermediate endpoint assays that shall examine changes in cellular, genomic, epigenomic, proteomic, and/or metabolomic profiles of immune system-cells (e.g. splenocytes, circulating lymphocytes, and tumor infiltrating lymphocytes) and other organ systems using relevant biospecimens, as specified in each awarded Task Order SOW. Endpoints to be examined shall include, but are not limited to, quantitative and/or qualitative profiles of specific cell population(s) in circulation (e.g.

circulating tumor cells) and/or organs, specific gene transcripts, miRNA and other small non-coding regulatory RNA species, DNA adducts, DNA methylation, histone modifications (e.g.

acetylation, deacetylation, ubiquitination, phosphorylation, etc.), exosomes, proteins with/without post-translational modifications (e.g. phosphorylation, ubiquitination, glycosylation, etc.), peptides, and other macromolecular complexes in laboratory animals treated or untreated with test agents as specified in the Task Order SOW.

4. The Contractor shall select and examine quantitative levels of appropriate intermediate endpoints that are proposed or understood to be involved in the immunomodulatory mechanism(s) of action of a given test agent, using the validated assays in relevant biospecimens as specified in each awarded Task Order SOW.

5. The Contractor shall select and examine quantitative levels of appropriate intermediate endpoints that are not directly involved in the MOA, but proposed or understood to be correlated with the test agent’s cancer preventive effects, using the validated assays in relevant biospecimens as specified in each awarded Task Order SOW.

6. The Contractor shall determine immune response kinetic endpoints directly related to test agents (e.g. vaccine or non-vaccine immunomodulatory agents) if specified in the Task Order

SOW.

7. The Contractor shall present/report all collected intermediate endpoint data in tabular and/or graphic forms, perform statistical analyses of the data, and shall provide a written commentary in the report regarding the results, as specified in each awarded Task Order.

Further, the Contractor shall correlate intermediate biomarker results with immunokinetic data, if applicable, and demonstrate ID effects. Furthermore, the Contractor shall correlate the ID effects with the effectiveness of a given agent and shall determine the immune correlates of protection, as specified in the Task Order SOW.

Base Contract Management Support Activities

These activities support parent contract requirements as stated in the contract. The scope includes management functions performed by the Contractor in support of NCI’s contract entitled

“PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL

EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS,” which occurs independent of other specific Task Orders to be awarded under the contract.

Requirements include:

1. Kick off Meeting

a. Participate in the initial parent contract kick-off meeting to be held in Rockville, Maryland. The kick-off meeting shall be attended by the Principal Investigator, key Contractor technical and business staff, the COR and his/her designees, and the Contracting Officer and/or his/her designees.

2. Annual Meeting

b. Participate in an annual meeting to be held in Rockville, Maryland at the COR’s discretion. The annual meeting shall be attended by the Principal Investigator and other relevant key Contractor staff, the COR and his/her designees, and the Contracting Officer and/or his/her designees. Task orders will be issued for this meeting on an annual or semi-annual basis during the contract period of performance.

Addendum to the Statement of Work: References

1) Office of Laboratory Animal Welfare, Office of the Director, NIH:

http://grants.nih.gov/grants/olaw/olaw.htm

2) Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International: http://www.aaalac.org/accreditation/

3) The Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals: http://grants.nih.gov/grants/olaw/references/phspol.htm

4) Guide for the Care and Use of Laboratory Animals:

https://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf

5) Animal Welfare Act and Animal Welfare Regulations established by the United States Department of Agriculture (USDA):

http://www.aphis.usda.gov/wps/portal/aphis/ourfocus/animalwelfare

6) “Biosafety in Microbiological and Biomedical Laboratories”, Centers for Disease Control and Prevention, and the National Institutes of Health, Fifth Edition 2009 http://www.cdc.gov/biosafety/publications/bmbl5/index.htm

7) NIH Guidelines for Research involving Recombinant or Synthetic Nucleic Acid Molecules: http://osp.od.nih.gov/sites/default/files/NIH_Guidelines.html

8) FDA Guidance for Industry: Integrated Summary of Effectiveness:

http://www.fda.gov/downloads/drugs/guidances/ucm079803.pdf

9) FDA Guidances on Biologics including Vaccines:

http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformatio n/Guidances/default.htm

10) FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines:

http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulator yInformation/Guidances/Vaccines/UCM278673.pdf

11) FDA Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products:

http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulator yInformation/Guidances/CellularandGeneTherapy/UCM376521.pdf

12) FDA Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications:

https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformati on/Guidances/Vaccines/ucm074770.htm http://grants.nih.gov/grants/olaw/olaw.htm http://www.aaalac.org/accreditation/ http://grants.nih.gov/grants/olaw/references/phspol.htm https://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf http://www.aphis.usda.gov/wps/portal/aphis/ourfocus/animalwelfare http://www.cdc.gov/biosafety/publications/bmbl5/index.htm http://osp.od.nih.gov/sites/default/files/NIH_Guidelines.html http://www.fda.gov/downloads/drugs/guidances/ucm079803.pdf http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM278673.pdf http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM278673.pdf http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM376521.pdf http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM376521.pdf https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074770.htm https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074770.htm

13) FDA Guidance for Industry: Content and Format of Chemistry, Manufacturing, and Controls Information and Establishment Description Information for Vaccine or Related Product:

http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceCo…